Related Experiment Video
Updated: May 16, 2026

Inner Mitochondrial Membrane Sensitivity to Na+ Reveals Partially Segmented Functional CoQ Pools
Published on: July 20, 2022
The effect of coenzyme Q10 in statin myopathy
Lukas Zlatohlavek1, Michal Vrablik, Barbora Grauova
13rd Department of Internal Medicine, Charles University and General Teaching Hospital, Prague, Czech Republic. lukas.zlatohlavek@lf1.cuni.cz
Objectives:
Statins significantly reduce CV morbidity and mortality. Unfortunately, one of the side effects of statins is myopathy, for which statins cannot be administered in sufficient doses or administered at all. The aim of this study was to demonstrate the effect of coenzyme Q10 in patients with statin myopathy.
Design/Setting:
Twenty eight patients aged 60.6±10.7 years were monitored (18 women and 10 men) and treated with different types and doses of statin. Muscle weakness and pain was monitored using a scale of one to ten, on which patients expressed the degree of their inconvenience. Examination of muscle problems was performed prior to administration of CQ10 and after 3 and 6 months of dosing. Statistical analysis was performed using Friedman test, Annova and Students t-test.
Results:
Pain decreased on average by 53.8% (p<0.0001), muscle weakness by 44.4% (p<0.0001). The CQ10 levels were increased by more than 194% (from 0,903 μg/ml to 2.66 μg/ml; p<0.0001).
Conclusion:
After a six-month administration of coenzyme Q10, muscle pain and sensitivity statistically significantly decreased.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Myasthenia Gravis ll: Pathophysiology
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug